AstraZeneca says U.S. data load for U.S. COVID-19 vaccine approval very big

FILE PHOTO: Vials of the AstraZeneca vaccine against the coronavirus disease (COVID-19) are seen during an organised media visit to the vaccination at Taoyuan Hospital in Taoyuan, Taiwan April 12, 2021. REUTERS/Ann Wang

LONDON (Reuters) - AstraZeneca is working as fast as possible to compile data on its COVID-19 vaccine to apply for U.S. approval but the dataset is very big, executives said on Friday as the drugmaker faces delays to its submission.

"There's a lot more data than just a Phase III study and so we're working as fast as we can to pull it all together and submit," said Mene Pangalos, executive vice president of BioPharmaceuticals R&D at AstraZeneca.